AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8992905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intubation, suxamethonium (1.5 mg/kg)
Number of subjects: 40
Study 8992905 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intubation, vecuronium (0.1 mg/kg)
Number of subjects: 40
Study 8992905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intubation, suxamethonium (1.5 mg/kg)
Number of subjects: 40
Study 8992905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intubation, vecuronium (0.1 mg/kg)
Number of subjects: 40
Study 1347866 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen
Number of subjects: 12
Study 3978827 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase
Number of subjects: 8
Study 3978827 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase
Number of subjects: 8
Study 30636636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (four lifestyle counselling sessions covering a balanced healthy diet, regular physical activity and self‐monitoring of weight gain)
Number of subjects: 2286
Study 30636636 — intervention group
Group type: COMPARATOR
Intervention: Control (leaflets with general recommendations for a healthy lifestyle during pregnancy)
Number of subjects: 2286
Study 30636636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 2286
Study 30636636 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 2286
Study 29044974 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LISAtri 839MP (Carl Zeiss Meditec)
Number of subjects: 52
Study 29044974 — intervention group
Group type: EXPERIMENTAL
Intervention: AT LISA 809 M (Carl Zeiss Meditec)
Number of subjects: 52
Study 29044974 — intervention group
Group type: EXPERIMENTAL
Intervention: ReSTOR SN6AD1 (Alcon)
Number of subjects: 52
Study 29044974 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 52
Study 26339899 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) with psychosocial support
Number of subjects: 101
Study 26339899 — intervention group
Group type: COMPARATOR
Intervention: Placebo with psychosocial support
Number of subjects: 101
Study 25168524 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of the posterior tibialis nerve (treatment group, n = 12)
Number of subjects: 24
Study 25168524 — intervention group
Group type: COMPARATOR
Intervention: General advice and stretching sessions (control group, n = 12)
Number of subjects: 24
Study 23893828 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Arm training with OT‐stim
Number of subjects: 28
Study 23893828 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Arm training alone
Number of subjects: 28
Study 23893828 — intervention group
Group type: COMPARATOR
Intervention: Usual therapy alone
Number of subjects: 28
Study 20800489 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward cane placement followed by the ipsilateral foot, then contralateral foot (FCI)
Number of subjects: 5
Study 20800489 — intervention group
Group type: EXPERIMENTAL
Intervention: Forward cane placement followed by the contralateral foot, then ipsilateral foot (FCC)
Number of subjects: 5
Study 20800489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral foot stepping up first, followed by the contralateral foot, then the cane (LCI)
Number of subjects: 5
Study 20800489 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral foot stepping up, followed by the ipsilateral foot, then the cane (LCC)
Number of subjects: 5
Study 20800489 — intervention group
Group type: COMPARATOR
Intervention: No cane (NC)
Number of subjects: 5
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal lens (ReSTOR, Alcon)
Number of subjects: 13
Study 18759213 — intervention group
Group type: COMPARATOR
Intervention: Monofocal lens (SA60AT, Alcon)
Number of subjects: 13
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: Binocular vision
Number of subjects: 13
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 13
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: General satisfaction
Number of subjects: 13
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: Far visual acuity satisfaction
Number of subjects: 13
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: Near visual acuity satisfaction
Number of subjects: 13
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of glasses
Number of subjects: 13
Study 18759213 — intervention group
Group type: EXPERIMENTAL
Intervention: Halos and glare
Number of subjects: 13
Study 17083352 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micro g ciclesonide
Number of subjects: 0
Study 17083352 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micro g ciclesonide
Number of subjects: 0
Study 17083352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14660453 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 16
Study 14660453 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 16
Study 10999558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone (1500 mg/d on day 1 and 1875 mg/d on days 2 to 8, administered three times per day)
Number of subjects: 52
Study 10999558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10999558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Number of subjects: 52
Study 7938556 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 7938556 — intervention group
Group type: EXPERIMENTAL
Intervention: MAOIs
Number of subjects: 0
Study 7938556 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective MAOI-A inhibitors (moclobemide, brofaromine)
Number of subjects: 0
Study 7938556 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 0
Study 7938556 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (MSH/ACTH analog)
Number of subjects: 0
Study 3130175 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant endocrine therapy (TAM 20 mg/day orally for 2 years in postmenopausal patients; oophorectomy before TAM in premenopausal patients)
Number of subjects: 692
Study 3130175 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (0.06 mg/kg of mitomycin C IV and 100 mg cyclophosphamide orally for 6 months repeated four times in 2 years)
Number of subjects: 692
Study 3130175 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (TAM with MMC + CPA chemotherapy)
Number of subjects: 692
Study 3130175 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy (TAM)
Number of subjects: 692
Study 3130175 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (MMC + CPA)
Number of subjects: 692
Study 3130175 — intervention group
Group type: COMPARATOR
Intervention: Chemoendocrine therapy (MMC + CPA + TAM)
Number of subjects: 692
Study 29706760 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus intensive task-specific hand training program with functional electrical stimulation for 8 weeks
Number of subjects: 10
Study 29706760 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 10
Study 26510663 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 538
Study 26819359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (n = 11; total cumulative dose of 180 mg)
Number of subjects: 21
Study 26819359 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (n = 10)
Number of subjects: 21
Study 23339047 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (hyperinsulinaemic normoglycaemic clamp protocol)
Number of subjects: 56
Study 23339047 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy with no additional dietary supplement)
Number of subjects: 56
Study 21303456 — intervention group
Group type: EXPERIMENTAL
Intervention: Levine technique
Number of subjects: 50
Study 21303456 — intervention group
Group type: COMPARATOR
Intervention: Z technique
Number of subjects: 50
Study 19446909 — intervention group
Group type: EXPERIMENTAL
Intervention: VCH-759 400mg t.i.d.
Number of subjects: 31
Study 19446909 — intervention group
Group type: EXPERIMENTAL
Intervention: VCH-759 800mg b.i.d.
Number of subjects: 31
Study 19446909 — intervention group
Group type: EXPERIMENTAL
Intervention: VCH-759 800mg t.i.d.
Number of subjects: 31
Study 19446909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 17277349 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy (atorvastatin 80 mg/day, simvastatin 80 mg/day, or rosuvastatin 20-40 mg/day)
Number of subjects: 110271
Study 14560320 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral THC (0, 10 mg) administered five times/day during marijuana abstinence (days 9-14)
Number of subjects: 14
Study 14560320 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex (0, 1500 mg/day) maintained for 29 days
Number of subjects: 14
Study 14560320 — intervention group
Group type: COMPARATOR
Intervention: Placebo THC
Number of subjects: 14
Study 14560320 — intervention group
Group type: COMPARATOR
Intervention: Placebo marijuana
Number of subjects: 14
Study 11296186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent dobutamine infusion (IDI), 10 micromin, as needed (mean, once every 16 days, lasting for 12 to 48 h)
Number of subjects: 22
Study 11296186 — intervention group
Group type: COMPARATOR
Intervention: Oral amiodarone, 400 mg/d, and IDI, 10 microg/kg/min, for 8 h every 7 days
Number of subjects: 22
Study 9632900 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (Sb) 200 micrograms
Number of subjects: 15
Study 9632900 — intervention group
Group type: EXPERIMENTAL
Intervention: ipratropium bromide (IB) 200 micrograms
Number of subjects: 15
Study 9632900 — intervention group
Group type: COMPARATOR
Intervention: placebo (freon propellant)
Number of subjects: 15
Study 10151166 — intervention group
Group type: EXPERIMENTAL
Intervention: Single house call by a health visitor 72 hours after discharge
Number of subjects: 0
Study 10151166 — intervention group
Group type: COMPARATOR
Intervention: Normal post-discharge care (Control)
Number of subjects: 0
Study 2235007 — intervention group
Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 40
Study 2235007 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol eyedrops
Number of subjects: 40
Study 2235007 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol eyedrops
Number of subjects: 40
Study 2235007 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol eyedrops
Number of subjects: 40
Study 849710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pericarditis
Number of subjects: 909
Study 849710 — intervention group
Group type: COMPARATOR
Intervention: Patients without pericarditis
Number of subjects: 909
Study 849710 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment
Number of subjects: 909
Study 31514564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy combined with power and strength exercises
Number of subjects: 30
Study 30847640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cit + Arg
Number of subjects: 24
Study 28437147 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation with a coach
Number of subjects: 28
Study 28437147 — intervention group
Group type: COMPARATOR
Intervention: Self-meditation with a CD
Number of subjects: 28
Study 26029985 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously every 6 months for 36 months
Number of subjects: 7808
Study 26029985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7808
Study 26029985 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 7808
Study 24330810 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for chronic dizziness
Number of subjects: 80
Study 24330810 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment for chronic dizziness
Number of subjects: 80
Study 21670727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol + dydrogesteron (37.5 µg/24h)
Number of subjects: 120
Study 21670727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol + medroxyprogesteron (50 µg/24h)
Number of subjects: 120
Study 21670727 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol + noretisteron (1mg)
Number of subjects: 120
Study 21670727 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 19424460 — intervention group
Group type: EXPERIMENTAL
Intervention: Health extension workers (HEWs) trained to identify TB suspects, collect sputum, and provide directly observed treatment in intervention kebeles.
Number of subjects: 318
Study 19424460 — intervention group
Group type: COMPARATOR
Intervention: Control group without HEWs involvement.
Number of subjects: 318
Study 16771791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 300 mg
Number of subjects: 248
Study 16771791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 450 mg
Number of subjects: 248
Study 16771791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 600 mg
Number of subjects: 248
Study 16771791 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 248
Study 15024300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5, 10, 20, 40, or 80 mg)
Number of subjects: 156
Study 15024300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (5-80 mg)
Number of subjects: 156
Study 15024300 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (doses > 5 mg)
Number of subjects: 156
Study 15024300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 11122839 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy regimens with radiotherapy
Number of subjects: 0
Study 11122839 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy regimens without radiotherapy
Number of subjects: 0
Study 11122839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic score for advanced-stage Hodgkin's disease
Number of subjects: 0
Study 9262937 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal and social rhythm therapy (IPSRT)
Number of subjects: 42
Study 9262937 — intervention group
Group type: COMPARATOR
Intervention: Standard medication clinic approach
Number of subjects: 42
Study 9262937 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pharmacotherapeutic protocol
Number of subjects: 42
Study 7967433 — intervention group
Group type: EXPERIMENTAL
Intervention: COALL therapy-protocol
Number of subjects: 286
Study 3483368 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 filled chocolate product (FCP)
Number of subjects: 18
Study 3483368 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 filled chocolate products (FCP)
Number of subjects: 18
Study 3483368 — intervention group
Group type: COMPARATOR
Intervention: 0 filled chocolate products (FCP)
Number of subjects: 18
Study 30332319 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) with four sets of four repetitions at 90% 1RM
Number of subjects: 53
Study 30332319 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric maximal strength training (eMST) with an augmented eccentric load of 150% 1RM
Number of subjects: 53
Study 30332319 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 53
Study 27363489 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 120
Study 27363489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 25031312 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitTxt (text messaging intervention)
Number of subjects: 862
Study 22889406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 181
Study 22889406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Number of subjects: 181
Study 20553948 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 91
Study 20553948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 91
Study 20553948 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 91
Study 18726159 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 18726159 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 18726159 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 18726159 — intervention group
Group type: COMPARATOR
Intervention: Psychotropic medications
Number of subjects: 0
Study 16431378 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg tablets (fasted state)
Number of subjects: 4
Study 16431378 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg tablets (fed state)
Number of subjects: 4
Study 16431378 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 50 mg tablets
Number of subjects: 4
Study 12860856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 30 mg
Number of subjects: 20
Study 12860856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10937118 — intervention group
Group type: EXPERIMENTAL
Intervention: Octyl-2-cyanoacrylate (Dermabond; Ethicon Inc, Somerville, NJ) tissue glue
Number of subjects: 20
Study 10937118 — intervention group
Group type: COMPARATOR
Intervention: 6.0 suture (polypropylene or fast-absorbing gut)
Number of subjects: 20
Study 8872133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol-lowering drug (simvastatin)
Number of subjects: 68
Study 8872133 — intervention group
Group type: COMPARATOR
Intervention: Subjects with TC > 249 mg/dl
Number of subjects: 68
Study 8872133 — intervention group
Group type: EXPERIMENTAL
Intervention: F1 + 2 plasma levels
Number of subjects: 68
Study 1518317 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP group
Number of subjects: 215
Study 1518317 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) group
Number of subjects: 215
Study 6638413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush treatment schedule
Number of subjects: 42
Study 6638413 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment schedule
Number of subjects: 42
Study 6638413 — intervention group
Group type: COMPARATOR
Intervention: HBV treatment
Number of subjects: 42
Study 6638413 — intervention group
Group type: COMPARATOR
Intervention: YJV treatment
Number of subjects: 42
Study 30227904 — intervention group
Group type: EXPERIMENTAL
Intervention: GC-FID method for determining ethanol in kombucha
Number of subjects: 8
Study 29150198 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 570
Study 29150198 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine-naloxone (BUP-NX)
Number of subjects: 570
Study 26529239 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness material about a person coping with suicidal ideation by getting professional help (low social similarity)
Number of subjects: 112
Study 26529239 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness material about a person coping with suicidal ideation by getting professional help (high social similarity)
Number of subjects: 112
Study 26529239 — intervention group
Group type: COMPARATOR
Intervention: Control group reading an article unrelated to suicide
Number of subjects: 112
Study 24886683 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal problem-solving therapy plus treatment-as-usual
Number of subjects: 60
Study 24886683 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual alone
Number of subjects: 60
Study 22784777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab (2.5, 5, or 10 mg)
Number of subjects: 690
Study 22784777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 690
Study 22784777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 690
Study 22784777 — intervention group
Group type: COMPARATOR
Intervention: Tanezumab and Placebo
Number of subjects: 690
Study 18855928 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-item odor identification test
Number of subjects: 102
Study 18855928 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 16-item identification test and detection threshold task
Number of subjects: 102
Study 17450372 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bicarbonate buffers (beta(nbi)) during exercise
Number of subjects: 34
Study 17450372 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bicarbonate buffers (beta(nbi)) during recovery
Number of subjects: 34
Study 17450372 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate buffering (beta(bi)) during and after exercise
Number of subjects: 34
Study 15241158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite and tricalcium phosphate coating
Number of subjects: 318
Study 15241158 — intervention group
Group type: COMPARATOR
Intervention: Control (no coating)
Number of subjects: 318
Study 11409308 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (ventriculoscopic operation)
Number of subjects: 88
Study 11409308 — intervention group
Group type: COMPARATOR
Intervention: Control (VP shunting)
Number of subjects: 88
Study 9777179 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 423
Study 9777179 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 423
Study 7935654 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine regimen (100 mg orally five times daily antepartum, 2 mg/kg intravenously during labor, 1 mg/kg/hour until delivery, and 2 mg/kg orally every six hours for six weeks for newborns)
Number of subjects: 477
Study 7935654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 7935654 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 477
Study 3067924 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 300 mg per day
Number of subjects: 40
Study 3067924 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg per day
Number of subjects: 40
Study 3067924 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen b.i.d. (twice daily)
Number of subjects: 40